Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Novo Nordisk A/S Common Stock (NY:NVO)

49.90 +0.75 (+1.53%)
Streaming Delayed Price Updated: 12:28 PM EST, Nov 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 15,781,602
Open 49.48
Bid (Size) 49.89 (200)
Ask (Size) 49.90 (400)
Prev. Close 49.15
Today's Range 49.32 - 50.43
52wk Range 45.05 - 112.52
Shares Outstanding N/A
Dividend Yield 4.40%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Novo Nordisk's $100 Million Coramitug Shows Promise In Reducing Heart Failure Biomarker
Novo Nordisk's Coramitug cut NT-proBNP levels and was well tolerated in a Phase 2 ATTR-CM trial, paving the way for its Phase 3 CLEOPATTRA study. 
Via Benzinga
Eli Lilly Drops CVS Health's Drug Benefit Plan For Employees Ahead Of 2026 Switch
Eli Lilly to drop CVS Health's drug benefit plan and move to Rightway in 2026 as Novo Nordisk cuts Wegovy prices in India to defend market share. 
Via Benzinga

Performance

YTD
-43.0%
-43.0%
1 Month
-13.2%
-13.2%
3 Month
+0.2%
+0.2%
6 Month
-23.7%
-23.7%
1 Year
-54.3%
-54.3%

More News

Read More
Why Metsera's Share Price Is Plummeting This Week
Via The Motley Fool
‘Somebody Knows Something:’ Viking Therapeutics Stock Pops To Nearly 3-Month High As Retail Traders Intensely Speculate On M&A Scenarios
Via Stocktwits
AMD, Oklo, AppLovin Corp, Viking Therapeutics And Novo Nordisk: Why These 5 Stocks Are On Investors' Radars Today
Via Benzinga
Topics Stocks
Novo Nordisk Rises Despite Metsera Loss, Slashes Wegovy Price In India
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Who's Winning the Intense Battle to Rule the White-Hot GLP-1 Drug Market?
Via The Motley Fool
Healthcare Sector Navigates Turbulent Waters: Innovation Surges Amidst Political Headwinds
Via MarketMinute
Topics Artificial Intelligence Economy Government
Metsera Tumbles After The Pfizer-Novo Buyout Battle Ends At $10 Billion
Via Investor's Business Daily
Topics Initial Public Offering
Monday.Com, Metsera, Profrac Holding And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
Why Viasat Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Novo Nordisk Loses Metsera Bidding War To Pfizer — But Retail Traders Aren’t Losing Faith
Via Stocktwits
Huge News for Eli Lilly Stock and Novo Nordisk Stock Investors as Companies Make Deal With Trump
Via The Motley Fool
Topics World Trade
Should You Buy Novo Nordisk After the Huge Investor Update?
Via The Motley Fool
Hims & Hers Revenue Continues to Surge. Is It Time to Buy the Stock?
Via The Motley Fool
Eli Lilly Strikes a Landmark Pricing Deal With the U.S. for Its Billion-Dollar Weight Loss Drugs. Here's What This Means for Investors.
Via The Motley Fool
Topics Government
Pfizer Clinches $10 Billion Deal To Buy Obesity Drug Maker Metsera, Outbidding Novo Nordisk In Fierce Battle For Weight-Loss Market Dominance
Via Benzinga
Deal Dispatch: From A Founder Comeback To Billion-Dollar Bids, This Week In M&A And Bankruptcy
Via Benzinga
Why Novo Nordisk Stock Is Sinking This Week
Via The Motley Fool
Topics Government World Trade
Eli Lilly's Investigational Obesity Drug Shows Up To 20% Weight Loss In Phase 2 Study, Analyst Sees It As Emerging Cornerstone In Obesity Treatment
Via Benzinga
FDA Fast-Tracks 6 More Drugs - Obesity And Cancer Drugs Included
Via Benzinga
The Weight-Loss Drugs Craze Is Going Strong. But Stock Investors Should Know A Few Things.
Via Investor's Business Daily
Topics Government
Can Hims & Hers Keep Its GLP-1 Edge After Trump Forces Lilly And Novo To Slash Prices? Wall Street Isn’t Convinced
Via Stocktwits
Topics Government World Trade
Eli Lilly Crushed Novo In Obesity Drug Battle—Trump Now Forces Price Cuts
Via Benzinga
Topics Government

Frequently Asked Questions

Is Novo Nordisk A/S Common Stock publicly traded?
Yes, Novo Nordisk A/S Common Stock is publicly traded.
What exchange does Novo Nordisk A/S Common Stock trade on?
Novo Nordisk A/S Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Novo Nordisk A/S Common Stock?
The ticker symbol for Novo Nordisk A/S Common Stock is NVO on the New York Stock Exchange
What is the current price of Novo Nordisk A/S Common Stock?
The current price of Novo Nordisk A/S Common Stock is 49.90
When was Novo Nordisk A/S Common Stock last traded?
The last trade of Novo Nordisk A/S Common Stock was at 11/12/25 12:28 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.